Omeros (NASDAQ:OMER) Rating Increased to Hold at Zacks Investment Research
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
A number of other equities research analysts have also issued reports on OMER. Wedbush set a $20.00 target price on Plymouth Industrial Reit and gave the company a buy rating in a research report on Monday, May 20th. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the company a buy rating in a research report on Tuesday, May 28th. BidaskClub lowered Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday. ValuEngine lowered Yirendai from a sell rating to a strong sell rating in a research report on Wednesday, June 26th. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $71.00 price target on shares of ExlService in a research report on Monday, May 6th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. Omeros currently has a consensus rating of Hold and a consensus target price of $25.80.
Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The company had revenue of $21.80 million during the quarter, compared to analyst estimates of $23.18 million. During the same quarter in the previous year, the company posted ($0.62) earnings per share. The business’s revenue was up 1271.1% compared to the same quarter last year. Equities analysts expect that Omeros will post -1.51 earnings per share for the current year.
Several hedge funds have recently bought and sold shares of OMER. Millennium Management LLC increased its holdings in shares of Omeros by 844.8% during the 4th quarter. Millennium Management LLC now owns 1,112,584 shares of the biopharmaceutical company’s stock worth $12,394,000 after acquiring an additional 994,829 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of Omeros by 49.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock worth $21,303,000 after acquiring an additional 632,840 shares during the last quarter. First Trust Advisors LP acquired a new position in shares of Omeros during the 4th quarter worth approximately $879,000. SG Americas Securities LLC increased its holdings in shares of Omeros by 68.5% during the 1st quarter. SG Americas Securities LLC now owns 144,444 shares of the biopharmaceutical company’s stock worth $2,509,000 after acquiring an additional 58,731 shares during the last quarter. Finally, Tibra Equities Europe Ltd acquired a new position in shares of Omeros during the 1st quarter worth approximately $771,000. 52.12% of the stock is currently owned by institutional investors and hedge funds.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.